Chronic kidney disease stage and cardiovascular and mortality events among older adults: The SPRINT trial

Authors

Valentina Turbay-Caballero, Advocate Health - MidwestFollow
Ana C. Ricardo, Division of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.
Jinsong Chen, Division of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.
Celestin Missikpode, Division of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.
James P. Lash, Division of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.
Gustavo Aroca-Martinez, Facultad de Ciencias de la Salud, Universidad Simón Bolivar, Barranquilla, Colombia.
Carlos G. Musso, Facultad de Ciencias de la Salud, Universidad Simón Bolivar, Barranquilla, Colombia.

Recommended Citation

Turbay-Caballero V, Ricardo AC, Chen J, et al. Chronic Kidney Disease Stage and Cardiovascular and Mortality Events Among Older Adults: The SPRINT Trial. Kidney Med. 2024;6(7):100845. Published 2024 May 18. doi:10.1016/j.xkme.2024.100845

Affiliations

Advocate Christ Medical Center

Abstract

Rationale & objective:The risk implications of the Kidney Disease: Improving Global Outcomes (KDIGO) chronic kidney disease classification in older adults are controversial. We evaluated the risk of adverse outcomes in this population across categories of estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR).

Study design:Prospective cohort.

Settings & participants:In total, 2,509 participants aged ≥75 years in the Systolic Blood Pressure Intervention Trial (SPRINT).

Exposure:KDIGO eGFR and UACR categories. We combined KDIGO categories G1 and G2, G3b and G4, as well as A2 and A3.

Outcomes:Primary SPRINT outcome (composite of myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes), and all-cause death.

Analytical approach:Multivariable Cox proportional hazard models.

Results:Mean age was 79.8 years, and 37.4% were female. The mean eGFR was 64.0 mL/min/1.73 m2, and the median UACR was 13.1 mg/g. In multivariable Cox proportional hazard analysis, compared with participants with eGFR ≥ 60 mL/min/1.73 m2 and UACR < 30 mg/g, there was no statistically significant difference in the risk of the primary outcome among participants with eGFR 45-59 or 15-44 mL/min/1.73 m2 and UACR < 30 mg/g. However, those with eGFR 45-59 or 15-44 mL/min/1.73 m2 and UACR ≥ 30 mg/g had higher risk of the primary outcome (HR [95% CI], 1.97 [1.27-3.04] and 3.32 [2.23-4.93], respectively). The risk for all-cause death was higher for each category of abnormal eGFR and UACR, with the highest risk observed among those with eGFR 15-44 mL/min/1.73 m2 and UACR ≥ 30 mg/g (3.34 [2.05-5.44]).

Limitations:Individuals with diabetes and urine protein >1 g/day were excluded from SPRINT.

Conclusion:Among older adults SPRINT participants, low eGFR without albuminuria was associated with higher mortality but not with increased risk of cardiovascular events. Additional studies are needed to evaluate an adapted chronic kidney disease stage-based risk stratification for older adults.

Type

Article

PubMed ID

38966681